ProtFI, an efficient frailty-trained proteomics-based biomarker of aging, robustly2 predicts age-related decline
Garst, S.; Kuiper, L. M.; van den Akker, E. B.; Berg, N. v. d.; Ghanbari, M.; Mooijaart, S. P.; Beekman, M.; Reinders, M.; Slagboom, P. E.; van Meurs, J.
Show abstract
Chronological age overlooks the heterogeneity in aging. In response, a wide range of molecular aging biomarkers has been developed to better capture an individual"s aging rate. Yet, a comprehensive comparison of modeling choices in the development of these biomarkers is lacking. In this study, we trained aging biomarkers on the Rockwood frailty index (FI) and all-cause mortality using UK Biobank Olink proteomics and metabolomics (1H-NMR) data (n=40,696). We systematically established the impact of model choice, target outcome, and molecular data source on several age-related outcomes. From this, we developed ProteinFrailty (ProtFI), an elastic net model using a minimal set of proteins to predict FI. ProtFI outperformed established aging biomarkers in relation to diverse outcomes, including incident cardiovascular disease, handgrip strength, and self-rated health, both in internal validation and two Dutch external cohorts (n=995, n=500). Our findings show that an efficient frailty-trained proteomic biomarker robustly predicts age-related decline.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.